Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) focuses its efforts on leveraging its proprietary technology to discover the structural secrets of complex sugars and other complex mixtures. The company’s novel approach to drug development and innovative tools have yielded a diversified product pipeline containing technology-enabled generic drugs, re-engineered drugs and novel drug candidates. Momenta’s strategic objective is to create near-term revenue opportunities that will fund longer-term discovery and development. For further information, visit the Company’s web site at www.momentapharma.com.
- 18 years ago
QualityStocks
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…